Johnson & Johnson (NYSE:JNJ) Stock Position Trimmed by Banque Pictet & Cie SA

Banque Pictet & Cie SA trimmed its stake in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 89.6% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 209,746 shares of the company’s stock after selling 1,806,568 shares during the quarter. Banque Pictet & Cie SA’s holdings in Johnson & Johnson were worth $37,173,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Family CFO Inc bought a new stake in shares of Johnson & Johnson during the 4th quarter worth about $26,000. Steward Financial Group LLC acquired a new position in shares of Johnson & Johnson in the 4th quarter worth approximately $34,000. Joseph P. Lucia & Associates LLC acquired a new position in shares of Johnson & Johnson in the 1st quarter worth approximately $38,000. Advocacy Wealth Management Services LLC grew its stake in shares of Johnson & Johnson by 41.4% in the 1st quarter. Advocacy Wealth Management Services LLC now owns 229 shares of the company’s stock worth $41,000 after purchasing an additional 67 shares during the last quarter. Finally, Gibson Wealth Advisors LLC acquired a new position in shares of Johnson & Johnson in the 4th quarter worth approximately $49,000. 68.78% of the stock is currently owned by institutional investors.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $171.79 on Friday. The company’s 50 day moving average price is $175.41 and its 200 day moving average price is $174.52. Johnson & Johnson has a 52 week low of $155.72 and a 52 week high of $186.69. The company has a market capitalization of $451.67 billion, a PE ratio of 25.01, a PEG ratio of 3.29 and a beta of 0.59. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.14 and a current ratio of 1.42.

Johnson & Johnson (NYSE:JNJGet Rating) last announced its quarterly earnings data on Tuesday, July 19th. The company reported $2.59 EPS for the quarter, beating analysts’ consensus estimates of $2.57 by $0.02. Johnson & Johnson had a net margin of 19.21% and a return on equity of 36.14%. The firm had revenue of $24.02 billion for the quarter, compared to the consensus estimate of $23.85 billion. During the same period in the previous year, the firm posted $2.48 earnings per share. The firm’s revenue was up 3.0% on a year-over-year basis. Research analysts expect that Johnson & Johnson will post 10.05 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 6th. Investors of record on Tuesday, August 23rd will be given a dividend of $1.13 per share. This represents a $4.52 dividend on an annualized basis and a yield of 2.63%. The ex-dividend date of this dividend is Monday, August 22nd. Johnson & Johnson’s payout ratio is presently 65.79%.

Analysts Set New Price Targets

JNJ has been the topic of several recent research reports. Raymond James lifted their price objective on shares of Johnson & Johnson from $195.00 to $196.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 20th. UBS Group lowered their price objective on shares of Johnson & Johnson from $185.00 to $180.00 in a research note on Thursday, July 21st. Credit Suisse Group lifted their target price on shares of Johnson & Johnson from $200.00 to $205.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 20th. SVB Leerink dropped their target price on shares of Johnson & Johnson from $200.00 to $194.00 in a research report on Wednesday, July 20th. Finally, Wells Fargo & Company lifted their target price on shares of Johnson & Johnson from $190.00 to $195.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 13th. Four research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $189.89.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 40,000 shares of Johnson & Johnson stock in a transaction that occurred on Friday, June 10th. The shares were sold at an average price of $173.00, for a total value of $6,920,000.00. Following the completion of the sale, the executive vice president now directly owns 71,311 shares in the company, valued at $12,336,803. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Johnson & Johnson news, CAO Robert J. Decker sold 8,462 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, May 26th. The shares were sold at an average price of $180.00, for a total value of $1,523,160.00. Following the completion of the sale, the chief accounting officer now directly owns 15,473 shares in the company, valued at $2,785,140. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Kathryn E. Wengel sold 40,000 shares of Johnson & Johnson stock in a transaction that occurred on Friday, June 10th. The shares were sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the completion of the sale, the executive vice president now owns 71,311 shares of the company’s stock, valued at $12,336,803. The disclosure for this sale can be found here. Corporate insiders own 0.35% of the company’s stock.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Articles

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.